NutriStem® hPSC XF Medium


  • Defined, xeno-free, serum-free medium

  • Designed for optimal growth and expansion of human iPS and hES cells

  • Customizable formulation

  • Custom scale-up services available

  • Scientific and regulatory support

  • Drug Master Files available

Name SKU Size Price Qty
NutriStem® hPSC XF Medium 05-100-1A 500 mL
$215.00
NutriStem® hPSC XF Medium 05-100-1B 100 mL
$65.00
NutriStem® hPSC XF Medium (Growth Factor-Free) 06-5100-01-1A 500 mL
$215.00
NutriStem® hPSC XF Medium 05-100-1A-20 20 x 500 mL
$3,800.00

Description

Details

Product Overview

NutriStem® hPSC XF Medium is a widely published, defined, xeno-free, serum-free cell culture medium designed to support the growth and expansion of human induced pluripotent stem (hiPS) and human embryonic stem (hES) cells. Protocols have been established around the world for applications ranging from derivation to differentiation. NutriStem® hPSC XF Medium offers the ability to culture cells in a completely xeno-free medium without the need for high levels of basic FGF and other stimulatory growth factors and cytokines. NutriStem® hPSC XF Medium exhibits a consistent media performance and predictable cellular behavior derived from a defined xeno-free formulation as well as increased reproducibility shown in long-term growth of over 50 passages.

Low-protein formulation that contains stable L-alanyl-L-glutamine and HSA.

NutriStem® hPSC XF Features

  • Defined, serum-free, and xeno-free 
  • Flexible and compatible with multiple matrices
  • Amenable to weekend-free culture
  • FDA Drug Master File (DMF) available, produced under cGMP
  • Enables efficient expansion and growth of hES and hiPS cells in feeder-free culture systems
  • Extensively tested and widely used on multiple hES and iPS cell lines, including H1, H9.2, I6, I3.2, and CL1
hESC were cultured in NutriStem® hPSC XF


Figure: 1 Human Embryonic Stem Cells (H1, passage 6) were seeded in 96-well plates (Matrigel coated) in BI's NutriStem® hPSC XF and competitor's media. Stem cell media were changed every 24 hours. Number of cells was determined using CyQuant™ cell proliferation assay kit.

Sample Data

Cell morphology

hiPS & hESC Normal Colony Morphology on NutriStem medium.

Figure: Normal Colony Morphology. H1 hES cells (top panel) and ACS-1014 hiPS cells (bottom panel) cultured in NutriStem® hPSC XF Medium on Matrigel-coated plates display colony morphologies typical of normal feeder-free hES and hiPS cell cultures, including a uniform colony of tightly compacted cells and distinct colony edges.

Immunostaining

Figure: H1 cell morphology and immunofluorescence analysis of hESC markers red SSEA-4, green OCT4 and blue DAPI. H1 cells stained positive for the expression of pluripotency markers.

Embryoid body formation

Figure: Embryoid bodies (EBs) were generated from H9.2 hES cells cultured for 16 passages in NutriStem® hPSC XF Medium on Matrigel matrix as an evaluation of pluripotency. The pluripotent H9.2 cells were suspended in serum-supplemented medium, where they spontaneously formed EBs containing cells of embryonic germ layers. The following cell types were identified by examination of the histological sections of 14-day-old EBs stained with H&E: (A) neural rosette (ectoderm), (B) neural rosette stained with Tubulin, (C) primitive blood vessels (mesoderm), and (D) megakaryocytes (mesoderm).

Taratoma formation

Figure: H9.2 hES cells were cultured for 11 passages in NutriStem® hPSC XF Medium using a human foreskin fibroblast (HFF) feeder layer. The hES cells were subsequently injected into the hind leg muscle of SCID-beige mice for in vitro evaluation of pluripotency. The following tissues from all three germ layers were identified in H&E-stained histological sections of the teratoma 12 weeks post-injection: (A) cartilage (mesoderm), (B) epithelium (endoderm), and (C) neural rosette (ectoderm).

Specifications

Specifications

Form Liquid
Brand NutriStem®
Storage Conditions Store at -20ºC
Shipping Conditions Dry Ice
Quality Control NutriStem® hPSC is routinely tested for optimal maintenance and expansion of undifferentiated hESCs. Additional standard evaluations are pH, osmolality, endotoxins and sterility tests.
Instructions for Use
  • Upon thawing, the medium may be stored at 2 - 8ºC for 14 days

  • Media should be aliquotted into smaller working volumes to avoid repeated freeze/thaw cycles 

  • Avoid exposure to light

 

Note: A common feeder-free basement membrane matrix is Matrigel, which is not xeno-free. Effective xeno-free alternatives to Matrigel is recombinant laminin, such as LaminStem(R) 521 (BI Cat. No. 05-753-1F) which has been validated to successfully culture human ES and iPS cells using NutriStem® hPSC XF medium.

Legal NutriStem® hPSC XF is registered as an In-vitro diagnostic (IVD) medical device. NutriStem® is a registered trademark of Biological Industries​.

A Drug Master File (DMF) for NutriStem® hPSC XF is available.

References

references

Growing Methods of hESC and iPSC (Derivation, Expansion, Scaling up, and Suspensions)

  1. R.M. Ferraro, et al. Generation of three iPSC lines from fibroblasts of a patient with Aicardi Goutières Syndrome mutated in TREX1 Stem Cell Research, 14 September 2019, https://doi.org/10.1016/j.scr.2019.101580
  2. I. Uçkay, et al. Regenerative Secretoma of Adipose-Derived Stem Cells from Ischemic Patients Journal of Stem Cell Research & Therapy  July 02, 2019 Volume 9 Issue 5 
  3. I. Klimanskaya, Embryonic Stem Cells: Derivation, Properties, and Challenges, Principles of Regenerative Medicine (Third Edition) 2019, chapter 7, pages 113-123
  4. K. Yoda et al. Optimization of the treatment conditions with glycogen synthase kinase-3 inhibitor towards enhancing the proliferation of human induced pluripotent stem cells while maintaining an undifferentiated state under feeder-free conditions. Journal of Bioscience and Bioengineering, October 2018
  5. X. Gao et al. A Rapid and Highly Efficient Method for the Isolation, Purification, and Passaging of Human-Induced Pluripotent Stem Cells. Cellular Reprogramming, Vol. 20, No. 5, 2018
  6. T. Teramura et al. Laser-assisted cell removing (LACR) technology contributes to the purification process of the undifferentiated cell fraction during pluripotent stem cell culture. Biochemical and Biophysical Research Communications, volume 503, Issue 4, 18 September 2018, pages 3114-3120
  7. Y.Y. Lipsitz et. al. Chemically controlled aggregation of pluripotent stem cells. Biotechnology and Bioengineering, 2018; 1-6
  8. F. Altieri et al.Production and characterization of CSSI003 (2961) human induced pluripotent stem cells (iPSCs) carrying a novel puntiform mutation in RAI1 gene, Causative of Smith–Magenis syndrome Stem Cell Research Volume 28, April 2018, Pages 153-156
  9. H. Albalushi et al. Laminin 521 Stabilizes the Pluripotency Expression Pattern of Human Embryonic Stem Cells Initially Derived on Feeder Cells Stem Cells International, Volume 2018
  10. O.M. Russell et al. Preferential amplification of a human mitochondrial DNA deletion in vitro and in vivo. Scientific Reports, volume 8, Article number: 1799 (2018)
  11. J. Rosati et al. Production and characterization of human induced pluripotent stem cells (iPSCs) from Joubert Syndrome: CSSi001-A (2850). Stem Cell Research, Volume 27, March 2018, Pages 74–77
  12. Maroof M Adil, David V Schaffer. Expansion of human pluripotent stem cells. Current Opinion in Chemical Engineering 2017, 15:24–35
  13. Tateno, H. et al. Development of a practical sandwich assay to detect human pluripotent stem cells using cell culture media Regenerative Therapy, Volume 6, June 2017, Pages 1–8
  14. Baker, D. et al. Detecting Genetic Mosaicism in Cultures of Human Pluripotent Stem Cells Stem Cell Reports, 2016
  15. Vega-Crespo, A., et al. Investigating the functionality of an OCT4-short response element in human induced pluripotent stem cells. Molecular Therapy — Methods & Clinical Development 3, Article number: 16050 (2016)
  16. Y.Y. Lipsitz, P.W. Zandstra, Human pluripotent stem cell process parameter optimization in a small scale suspensionbioreactor. BMC Proceedings, 9(Suppl 9), O10, 2015
  17. S. Gregory et al. Autophagic response to cell culture stress in pluripotent stem cells. Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2015.09.080, 2015
  18. N. Desai, P Rambhia and A. Gishto, Human embryonic stem cell cultivation: historical perspective and evolutionof xeno-free culture systems. Reproductive Biology and Endocrinology 13.1 (2015): 9.
  19. T. Yokobori et al., Intestinal epithelial culture under an air-liquid interface: a tool for studying human and mouse esophagi. Diseases of the Esophagus, doi: 10.1111/dote.12346. 2015
  20. L. Healy, L Ruban, Derivation of Induced Pluripotent Stem Cells, Atlas of Human Pluripotent Stem Cells in Culture, pp 149-165. Springer US 2015
  21. W. Siqin et al. Spider silk for xeno-free long-term self-renewal and differentiation of human pluripotent stem cells. Biomaterials 35.30 (2014): 8496-8502.
  22. G. Finesilver, M. Kahana, E. Mitrani. Kidney-Specific Micro-Scaffolds and Kidney Derived Serum FreeConditioned Media support in vitro Expansion, Differentiation, and Organization of Human Embryonic Stem Cells. Tissue Engineering Part C: Methods. -Not available-, ahead of print. doi:10.1089/ten.TEC.2013.0574.
  23. M. Amit, J. Itskovitz-Eldor. Atlas of Human Pluripotent Stem Cells: Derivation and Culturing. Stem Cell Biology and Regenerative Medicine, 2012
  24. R. Bergström, Xeno-free culture of human pluripotent stem cells, Methods Mol Biol. 2011;767:125-36
  25. J.Collins et al,. Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells withSynthetic Modified mRNA. Cell Stem Cell 7 (5): 618-630 (2010).
  26. K. Jacobs et al. Higher-Density Culture in Human Embryonic Stem Cells Results in DNA Damage and GenomeInstability. Stem Cell Reports: 6(3), pp 330–341, 2016


Differentiation of Pluripotent Stem Cells

  1. A. Shoval, et al. Anti‐VEGF‐Aptamer Modified C‐Dots—A Hybrid Nanocomposite for Topical Treatment of Ocular Vascular Disorders Wiley Online Library, 12 August 2019 https://doi.org/10.1002/smll.201902776
  2. Y. Chemla et al., Gold nanoparticles for multimodal high-resolution imaging of transplanted cells for retinal replacement therapy NANOMEDICINE, VOL. 14, NO. 14, 24 Jul 2019, https://doi.org/10.2217/nnm-2018-0299
  3. P.Ni et al. iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function Molecular Psychiatry, 31 July 2019
  4. L. P. Liu et al. Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous Transplantation Volume 27, Issue 2, Cell Reports, 9 April 2019, Pages 455-466.e5  
  5. C. M. Sellgren et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nature Neurosciencevolume 22, pages374–385 (2019)
  6. S. Su et al. A Renewable Source of Human Beige Adipocytes for Development of Therapies to Treat Metabolic Syndrome. Cell Reports, Volume 25, Issue 11, Pages 2935-3230, 2018
  7. SL Ji and SB Tang, Differentiation of retinal ganglion cells from induced pluripotent stem cells: a review. Int J Ophthalmol. 2019; 12(1): 152–160.
  8. A. MarKus et al. An optimized protocol for generating labeled and transplantable photoreceptor precursors from human embryonic stem cells. Experimental Eye Research, volume 180, March 2019, pages 29-38
  9. Z. Shao et al. Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell–derived cortical interneurons from subjects with schizophrenia. Nature Neuroscience volume 22, pages 229–242 (2019)
  10. M. Tewary, Engineered In vitro models of post-implantation human development to elucidate mechanisms of self-organized fate specification during embryogenesis. A thesis submitted, Institute of Biomaterials and Biomedical Engineering, University of Toronto, 2018
  11. D.L. McPhie et al. Oligodendrocyte differentiation of induced pluripotent stem cells derived from subjects with schizophrenias implicate abnormalities in development Translational Psychiatryvolume 8, Article number: 230 (2018)
  12. J. Ameri et al. Efficient Generation of Glucose-Responsive Beta Cells from Isolated GP2+ Human Pancreatic ProgenitorsCell Reports, Volume 19
  13. R. De santis et al. Direct conversion of human pluripotent stem cells into cranial motor neurons using a piggyBac vector. Stem Cell Research 29 (2018) 189–196
  14. K.M. Gray et al. Self-oligomerization regulates stability of Survival Motor Neuron (SMN) protein isoforms by sequestering an SCFSlmb degron. Molecular Biology of the Cell, 2017 mbc.E17-11-0627
  15. E. Welby et al. Isolation and Comparative Transcriptome Analysis of Human Fetal and iPSC-Derived Cone Photoreceptor Cells. Stem Cell Reports (2017), https://doi.org/10.1016/j.stemcr.2017.10.018
  16. R. De-Santis et. al. FUS Mutant Human Motoneurons Display Altered Transcriptome and microRNA Pathways with Implications for ALS Pathogenesis. Stem Cell Reports (2017), https://doi.org/10.1016/j.stemcr.2017.09.004
  17. R.A. Hazim et al. Differentiation of RPE cells from integration-free iPS cells and their cell biological characterization. Stem Cell Research & Therapy 2017
  18. S. Petrus-Reurer et al. Integration of Subretinal Suspension Transplants of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in a Large-Eyed Model of Geographic Atrophy. Retinal Cell Biology, February 2017
  19. X. Yuan et al. A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model, PLOS ONE, 2017
  20. Lenzi, J., et al. Differentiation of control and ALS mutant human iPSCs into functional skeletal muscle cells, a tool for the study of neuromuscolar diseases. Stem Cell Research: Volume 17, Issue 1, Pages 140–147, 2016.
  21. K. Alessandri et. al. A 3D printed microfluidic device for production of functionalized hydrogel microcapsules forculture and differentiation of human Neuronal Stem Cells (hNSC). Lab on a Chip: 16(9), 2016
  22. D. Voulgaris, Evaluation of Small Molecules for Neuroectoderm differentiation & patterning using Factorial Experimental Design. Master Thesis in Applied Physics, Department of Physics, Division of Biological Physics, Chalmers University of Technology, Göteborg, Sweden 2016
  23. P. Bergström et al. Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation, Scientific Reports, 2016
  24. Tieng, V. ae al. Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase, Molecular Therapy — Methods & Clinical Development 6, Article number: 16069, 2016
  25. Brykczynska, U, et al. CGG Repeat-Induced FMR1 Silencing Depends on the Expansion Size in Human iPSCs and Neurons Carrying Unmethylated Full Mutations Stem Cell Reports, 2016
  26. Sellgren ,C.M. et al. Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors Molecular Psychiatry, 2016
  27. Cosset, E. et al. Human tissue engineering allows the identification of active miRNA regulators of glioblastoma aggressiveness Biomaterials, 2016
  28. M. Di Salvio et al. Pur-alpha functionally interacts with FUS carrying ALS-associated mutations. Cell Death & Disease, 2015
  29. A. Reyes, et al. Xeno-Free and Defined Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Functionally Integrate in a Large-Eyed Preclinical Model Plaza. Stem Cell Reports: Volume 6, Issue 1, p9–17, 2015
  30. A. J. Schwab, A.D. Ebert, Sensory Neurons Do Not Induce Motor Neuron Loss in a Human Stem Cell Model of SpinalMuscular Atrophy. PLoS One. 2014; 9(7): e103112
  31. H.X. Nguyen et al., Induction of early neural precursors and derivation of tripotent neural stem cells from humanpluripotent stem cells under xeno-free conditions. Journal of Comparative Neurology: Volume 522, Issue 12, pp 2767–2783, 2014
  32. A. Kurtz, A. Bosio, and S. Knoebel. Highly efficient differentiation of hPSC into hepatocyte-like cellsby selection of CXCR4 (CD184) definitive endoderm (DE) cells


Cardiomyocyte differentiation

  1. N. Noor, et al. 3D Printing of Personalized Thick and Perfusable Cardiac Patches and Hearts Adv. Sci. 2019, 6, 1900344
  2. D. Hayoun‐Neeman et al. Exploring peptide‐functionalized alginate scaffolds for engineering cardiac tissue from human embryonic stem cell‐derived cardiomyocytes in serum‐free medium Polymers for Advanced Technologies,12 April 2019 https://doi.org/10.1002/pat.4602 
  3. L. Yap et al. In Vivo Generation of Post-infarct Human Cardiac Muscle by Laminin-Promoted Cardiovascular Progenitors. Cell Reports, Volume 26, Issue 12, 19 March 2019, Pages 3231-3245.e9
  4. A.C.Y. Chang et al. Telomere shortening is a hallmark of genetic cardiomyopathies. PNAS September 11, 2018
  5. S Rajasingh et al. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity. Acta Pharmacologistarca Sinica, 2018
  6. R. Ophir et al. Inflammation And Contractility Are Altered By Obstructive Sleep Apnea Children's Serum, In Human Embryonic Stem Cell Derived Cardiomyocytes. American Journal of Respiratory and Critical Care Medicine 2017
  7. J. Kristensson, Optimization of Growth Conditions for Expansion of Cardiac Stem Cells Resident in the Adult Human Heart. Master’s thesis in Biotechnology, Department of Physics, Division of Biological Physics, Chalmers University of Technology, Gothenburg, Sweden 2016
  8. S. Rajasingh et al. Generation of Functional Cardiomyocytes from Efficiently Generated Human iPSCs and a Novel Method of Measuring Contractility. PloS one 10.8, 2015: e0134093
  9. L. Jacquet et al. Three Huntington’s Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes. PloS one 10.5, 2015
  10. V. Bellamy et al., Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold, The Journal of Heart and Lung Transplantation, 2014, in press
  11. E. Di Pasquale et al. Generation of human cardiomyocytes: a differentiation protocol for feeder-free human induced pluripotent stem cells. JoVE (Journal of Visualized Experiments) 76 (2013): e50429-e50429
  12. P.W. Burridge and E.T Zambidis. Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. Pluripotent Stem Cells: Methods and Protocols. Methods in Molecular Biology, volume 997, pp 149-161, Humana Press, 2013.


Gene Editing

  1. W. Supharattanasitthi et al. CRISPR/Cas9-mediated one step bi-allelic change of genomic DNA in iPSCs and human RPE cells in vitro with dual antibiotic selection. Scientific Reportsvolume 9, Article number: 174 (2019)
  2. Sweeney, CL et al.Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction,Molecular Therapy, 2017
  3. J. Lenzi et al., ALS mutant FUS proteins are recruited into stress granules in induced Pluripotent Stem Cells (iPSCs) derived motoneurons. Disease Models & Mechanisms: 8, 755-766, 2015
  4. T. Cerbini et al., Transfection, Selection, and Colony-picking of Human Induced Pluripotent Stem Cells TALEN-targetedwith a GFP Gene into the AAVS1 Safe Harbor, JoVE (Journal of Visualized Experiments), 2015


Proteins and Antibodies Expression and Isolation

  1. E. Gelali et al., iFISH is a publically available resource enabling versatile DNA FISH to study genome architecture Nature Communications, volume 10, 1636, (2019)  
  2. C.Markouli et al., Gain of 20q11.21 in Human Pluripotent Stem Cells Impairs TGF-β-Dependent Neuroectodermal Commitment  Stem Cell Reports,Volume 13, Issue 1, 9 July 2019, Pages 163-176
  3. A. DePalma, Culture Media Purpose-Fit for New TherapiesGenetic Engineering & Biotechnology News, March 2018
  4. D.R. Riordon and K.R. Boheler, Immunophenotyping of Live Human Pluripotent Stem Cells by Flow Cytometry. In: Boheler K., Gundry R. (eds) The Surfaceome. Methods in Molecular Biology, vol 1722. Humana Press, New York, NY, 2018
  5. N.Y. Thakar et al., TRAF2 recruitment via T61 in CD30 drives NFkB activation and enhances hESC survival andproliferation, Molecular Biology of the Cell: 26(5):993-1006 2015
  6. Abcam, Immunocytochemistry / Immunofluorescence abreview for Anti-Oct4 antibody - ChIP Grade. Abcam website

Drug Screening

  1. Z. Ye et al., Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoieticprogenitors

Organoids

  1. P. Tai, et al. The Development and Applications of a Dual Optical Imaging System for Studying Glioma Stem Cells Molecular Imaging Volume: 18, September 3, 2019, https://doi.org/10.1177/1536012119870899
  2. E. Cosset et al. Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases JoVE, ISSUE 148, 10.3791/59682, 6/28/2019
  3. K. Maliszewska-Olejniczak eta al. Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. Cytotechnology (2018). https://doi.org/10.1007/s10616-018-0273-x
  4. D.C. Wilkinson et. al. Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling. Stem cells translational medicine, 6(2), 2017
  5. Tieng, V. et al.Engineering of Midbrain Organoids Containing Long-Lived Dopaminergic Neurons. Stem Cells and Development. February 2014, 23(13): 1535-1547.
  6. K. Maliszewska-Olejniczak et al. Three-Dimensional Cell Culture Model Utilization in Renal Carcinoma Cancer Stem Cell Research. In: Baratta M. (eds) Epithelial Cell Culture. Methods in Molecular Biology, vol 1817. Humana Press, New York, NY


Different Basement Matrices

  1. N. J. W. Penfold, et al. Emerging Trends in Polymerization-Induced Self-Assembly ACS Macro Lett.20198XXX1029-1054, August 7, 2019, https://doi.org/10.1021/acsmacrolett.9b00464
  2. U. Johansson, et al. Assembly of functionalized silk together with cells to obtain proliferative 3D cultures integrated in a network of ECM-like microfibers Scientific Reports, volume 9, Article number: 6291 (2019)
  3. N.J.W. Penfold et al. Thermoreversible Block Copolymer Worm Gels Using Binary Mixtures of PEG Stabilizer Blocks. Macromolecules, DOI: 10.1021/acs.macromol.8b02491, 2019
  4. Y Qin, et al. Laminins and cancer stem cells: partners in crime? Seminars in Cancer Biology, 2016
  5. S. Wu et al. Efficient passage of human pluripotent stem cells on spider silk matrices under xeno-free conditions. Cellular and Molecular Life Sciences: 73(7):1479-88, 2015
  6. O. Simonson. Use of Genes and Cells in Regenerative Medicine. Karolinska Institutet, 2015
  7. Nacalai USA Inc. Vitronectin-398™ (Xeno-free). Nacalai USA website
  8. S. Rodin et al., Monolayer culturing and cloning of human pluripotent stem cells on laminin-521–based matrices under xeno-free and chemically defined conditions. Nature Protocols 9, 2354–2368 (2014) doi:10.1038/ nprot.2014.159
  9. Rodin S, et al. Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin matrix in defined and xeno-free environment. Nat Commun. 5:3195. doi: 10.1038/ncomms4195, 2014
  10. StemAdhere™ Defined Matrix for hPSC. Primorigen Biosciences website.
  11. I. lenz et al., Automated 3D Culture to Undifferentiated hESC. (Scientific Poster)
  12. J.L. Weber et al,. The Corning® Synthemax™ Surface: A Synthetic, Xeno-Free Surface for Long-Term Self-Renewal of Human Embryonic Stem Cells in Defined Media. presented in 2010 world stem cell summit


Induction of Pluripotency of hESC and iPSC

  1. L. Gaetana, et al. Generation of 3 clones of induced pluripotent stem cells (iPSCs) from a patient affected by Crohn's disease Stem Cell Research, 23 August 2019, https://doi.org/10.1016/j.scr.2019.101548  
  2. N. Kolundzic, et al. Induced pluripotent stem cell line heterozygous for p.R501X mutation in filaggrin: KCLi003-A Stem Cell Research, 7 August 2019, 101527, https://doi.org/10.1016/j.scr.2019.101527

  3. M. Nakajima et al. Establishment of induced pluripotent stem cells from common marmoset fibroblasts by RNA-based reprogramming Biochemical and Biophysical Research Communications Volume 515, Issue 4, 6 August 2019, Pages 593-599

  4. F. Altieri et al. Production and characterization of human induced pluripotent stem cells (iPSC) CSSi007-A (4383) from Joubert Syndrome Stem Cell Research, Volume 38, July 2019, 101480
  5. A.M.Sacco et al. Diversity of dermal fibroblasts as major determinant of variability in cell reprogramming  Journal of Cellular and Molecular Medicine, 2019;23:4256- 4268. 
  6. T. Klein et al. Generation of two induced pluripotent stem cell lines from skin fibroblasts of sisters carrying a c.1094C>A variation in the SCN10A gene potentially associated with small fiber neuropathy. Stem Cell Research, Volume 35, March 2019
  7. G. Piovani et al. Generation of induced pluripotent stem cells (iPSCs) from patient with Cri du Chat Syndrome. Stem Cell Research, Volume 35, March 2019
  8. T. Klein at al. Generation of the human induced pluripotent stem cell line UKWNLi002-A from dermal fibroblasts of a woman with a heterozygous c.608 C>T (p.Thr203Met) mutation in exon 3 of the nerve growth factor gene potentially associated with hereditary sensory and autonomic neuropathy type 5. Stem Cell Research, available online 12 October 2018
  9. X. Gao et al. Generation of nine induced pluripotent stem cell lines as an ethnic diversity panel Stem Cell Research, Volume 31, August 2018, Pages 193-196
  10. S.T Chandrabose et al. Amenable epigenetic traits of dental pulp stem cells underlie high capability of xeno-free episomal reprogramming. Stem Cell Research & Therapy, 2018 9:68
  11. H. Naaman et. al. Measles Virus Persistent Infection of Human Induced Pluripotent Stem Cells. Cellular ReprogrammingVol. 20, No. 1, 2018
  12. X. Gao et. al. Comparative transcriptomic analysis of endothelial progenitor cells derived from umbilical cord blood and adult peripheral blood: Implications for the generation of induced pluripotent stem cells. Stem Cell Research, 2017
  13. M.V. Krivega et al. Cyclin E1 plays a key role in balancing between totipotency and differentiation in human embryonic cells. Mol. Hum. Reprod, 2015
  14. S. Herz, Optimization of RNA-based transgene expression by targeting Protein Kinase R. Dissertation for the degree “Doctor rerum naturalium”, 2015
  15. S. Eminli-Meissner et al. A novel four transfection protocol for deriving iPS cell lines from human blood- derivedendothelial progenitor cells (EPCs) and adult human dermal fibroblasts using a cocktail of non-modified reprogrammingand immune evasion mRNAs. Sientific Poster, REPROCELL, 2015
  16. M. Brouwer et al. Choices for Induction of Pluripotency: Recent Developments in Human Induced Pluripotent StemCell Reprogramming Strategies. Stem Cell Reviews and Reports: Volume 12, Issue 1, pp 54–72, 2015
  17. R. S. Song et al. Generation, Expansion, and Differentiation of Human Induced Pluripotent Stem Cells (hiPSCs) Derived from the Umbilical Cords of Newborns. Current protocols in stem cell biology (2013): UNIT 1C.16.
  18. Warren, L., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618-630, 2010
  19. S. Sugii et al., Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells. PNAS February 23, 2010 vol. 107 no. 8 3558-3563


Clinical Applications- Derivation and Expansion of hESC and IPSC

  1. Q. Gu et al. Accreditation of Biosafe Clinical-Grade Human Embryonic Stem Cells According to Chinese Regulations. Stem Cell Reports. 2017 Jul 11; 9(1): 366–380.
  2. L. de Oñate et al. 2015. Research on Skeletal Muscle Diseases Using Pluripotent Stem Cells. DOI: 10.5772/60902
  3. P. Menasché et al., Towards a Clinical Use of Human Embryonic Stem Cell-Derived Cardiac Progenitors:A Translational Experience. European Heart Journal: Volume 36, Issue 12, pp 743-50, 2015
  4. P. Menasché et al.Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. European heart journal (2015): ehv189.
  5. T. Seki, K. Fukuda, Methods of induced pluripotent stem cells for clinical application, World Journal of Stem Cells: Volume 7, Issue 1, pp 116–125, 2015
  6. Y. Luo et al.,Stable Enhanced Green Fluorescent Protein Expression After Differentiation and Transplantation of Reporter Human Induced Pluripotent Stem Cells Generated by AAVS1 Transcription Activator-Like Effector Nucleases, STEM CELLS Translational Medicine: Volume 3, Issue 7, pp 821-35, 2014
  7. J. Durruthy-Durruthy et al. Rapid and Efficient Conversion of Integration-Free Human Induced Pluripotent Stem Cells to GMP-Grade Culture Conditions. PlOS one: http://dx.doi.org/10.1371/journal.pone.0094231, 2014
  8. H. Tateno et al. A medium hyperglycosylated podocalyxin enables noninvasive and quantitative detection of tumorigenic human pluripotent stem cells. Scientific Reports 4, Article number: 4069, 2014
  9. S. Abbasalizadeh, H. Baharvand. Technologies progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnology Advances: Volume 31, Issue 8, pp 1600-23, 2013.
  10. J. P. Awe et al. Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Research & Therapy, 2013, 4:87
  11. O. Hovatta. Infectious problems associated with transplantation of cells differentiated from pluripotent stem cells. Seminars in Immunopathology: Volume 33, Issue 6, pp 627-30, April 2011
  12. S. Ström. Optimisation of human embryonic stem cell derivation and culture – towards clinical quality. Karolinska Institutet, Stockholm, Sweden, 2010


Animal Models

  1. M. Nakanishi , et al. Human Pluripotency Is Initiated and Preserved by a Unique Subset of Founder Cells Cell, Volume 177, Issue 4, 2 May 2019, Pages 910-924.e22
  2. W. Zhang, et al. Distinct MicroRNA Expression Signatures of Porcine Induced Pluripotent Stem Cells under Mouse and Human ESC Culture Conditions. PLOS ONE, 2016


Patents

  1. A. C. Brown , METHODS, COMPOSITIONS, AND KITS FOR PRODUCING BEIGE ADIPOCYTES AND TREATING METABOLIC DISORDERS US Patent App. 16/245298,  08/29/2019  
  2. M. fink, et al. METHODS AND COMPOSITIONS FOR IMMUNOMODULATION US Patent App. 20190247440 08/15/2019
  3. K.H. Krause et al. ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS  US Patent App. 16/204320, 05/30/2019
  4. K. Tryggvason et al. DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND CARDIAC PROGENITOR CELLS INTO STRIATED CARDIOMYOCYTE FIBERS USING LAMININS LN-511, LN-521 AND LN-221. US Patent App. 16/015,336, 2019
  5. H.M. Blau and C.Y.A. Chang, IDENTIFICATION OF TELOMERE LENGTH AS A DIAGNOSTIC BIOMARKER FOR HERITABLE CARDIOMYOPATHIES. US Patent App. 16/078,486, 2019
  6. C. H. Kim, METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS AND INDUCED PLURIPOTENT STEM CELLS PRODUCED THEREBY. US Patent App. 15/716,614, 2019
  7. U. Sahin et al. Method for cellular RNA expression. US Patent App. 14/706,228, 2019
  8. M. Amit & J. Itskovitz-Eldor, Methods for expanding and maintaining human pluripotent stem cells (PSCs) in an undifferentiated state in a single cell suspension culture. US Patent App. 10/214,722, 2019
  9. G. M. de Peppo, Perfusion bioreactor. US Patent App. 14/959,950, 2019
  10. K.Tryggvason et al. Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins ln-511, ln-521 and ln-221. US Patent App. 16/015,309, 2018
  11. J. Mata-Fink et al. Methods and compositions for immunomodulationUS Patent App US20180271910A1
  12. K. Tanabe et al. Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells. US Patent App US20180273891A1
  13. O Bohana-kashtan. Preparation of Photoreceptors for the Treatment of Retinal Diseases. United States Patent Application 20180228846
  14. O. Bohana-kashtan, O. Wiser. Preparation of Retinal Pigment Epithelium Cells. United States Patent Application 20180230426
  15. B.E. Reubinoff, O. Singer, Large Scale Production of Retinal Pigment Epithelial Cells United States Patent Application 20180216064
  16. D Clegg et al. Methods of Culturing Retinal Pigmented Epithelium Cells, Including Xeno-Free Production, RPE Enrichment, and Cryopreservation. United States Patent Application 20180087029, 2018
  17. H. Tateno et. al. Method and kit for detecting stem cell. US Patent Application 15548921, 2018
  18. J. Mata-fink et al. Methods and Compositions For Immunomodulation. US Patent Application 20170020926, 2017
  19. Bailly, J., et al. Method for differentiation of pluripotent stem cells into multi-competent renal precursors. US Patent 20,160,145,578, 2016
  20. K. Tryggvason et al. Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins LN-511, LN-521 and LN-221. US Patent Application 20160122717, 2016
  21. D. Keefe et al. A Method for a Single Cell Analysis of Telomere Length. US Patent Application 20160032360, 2016
  22. Dietrich M. EGLI, Methods for making and using modified oocytes . US Patent Application 20140308257, 2016
  23. M. Mikkola et. al. A Method for Generating Induced Pluripotent Stem Cells. US Patent Application 20160068818, 2016
  24. H Tateno et al. Undifferentiated Cell Detection Method and Complex Carbohydrate Detection Method. US Patent Application 20150204870, 2015
  25. O. Hovatta, K. Tryggvason, Methods of Producing RPE Cells. US Patent Application 20150299653, 2015
  26. A. De Fougerolles, S.M. Elbashir, Delivery and Formulation of Engineered Nucleic Acids, US Patent Application 20150017211, 2015
  27. Sahin, U., et al. Diagnosis and therapy of cancer involving cancer stem cells. US Patent Application 20150314018, 2015
  28. U. Sahin et al. Method for Cellular RNA Expression. US Patent Application 20150314018, 2015
  29. M.F Yanik, M. Angel. Methods for Transfecting Cells With Nucleic Acids. US Patent Application 20140073053, 2014
  30. C.E Buensuceso et al., Induced Pluripotent Stem Cells Prepared from Human Kidney-Derived Cells. US Patent Application 20140073049, 2014
  31. C. Buensuceso et al., Induced Pluripotent Stem Cells from Human Umbilical Cord Tissue-Derived Cells. US Patent Application 20130157365, 2013
  32. A. De Fougerolles, S.M. Elbashir, J.P. Schrum. Modified Polynucleotided for the Production of Factor IX. US Patent Application 20130245103, 2013
  33. M. Amit, J. Itskovitz-eldor. Novel Methods and Culture Media for Culturing Pluripotent Stem Cells. US Patent Application 20130236961, 2013
  34. E. Zambidis, P Burridge. Compositions and Methods of Generating a Differentiated Mesodermal Cell. US Patent Application 20130136721, 2013.

Documentation

Material Safety Data Sheet

Manuals and Protocols

Webinars & Videos

Product Literature

Frequently Asked Questions

Certificate of Analysis

Certificates of Analysis (COA's) describe quality control data for specific product lots.
Please enter the product lot number and click search.
If your search does not return any results, please contact us for assistance.

Reviews

Customer Reviews (1)

Five Stars, highly recommendedReview by John
Quality
Worked very well for us. High quality medium that gave us the most control over our cells. Ingredients you need. Highly recommended. (Posted on 10/24/2017)

Write Your Own Review

You're reviewing: NutriStem® hPSC XF Medium

How do you rate this product? *

  1 star 2 stars 3 stars 4 stars 5 stars
Quality

You may also be interested in the following product(s)